Fred Hutchinson Cancer Center is an independent, nonprofit organization providing adult cancer treatment and groundbreaking research focused on cancer and infectious diseases. Based in Seattle, Fred Hutch is the only National Cancer Institute-designated cancer center in Washington.
With a track record of global leadership in bone marrow transplantation, HIV/AIDS prevention, immunotherapy and COVID-19 vaccines, Fred Hutch has earned a reputation as one of the world’s leading cancer, infectious disease and biomedical research centers. Fred Hutch operates eight clinical care sites that provide medical oncology, infusion, radiation, proton therapy and related services, and network affiliations with hospitals in five states. Together, our fully integrated research and clinical care teams seek to discover new cures to the world’s deadliest diseases and make life beyond cancer a reality.
At Fred Hutch we value collaboration, compassion, determination, excellence, innovation, integrity and respect. These values are grounded in and expressed through the principles of diversity, equity and inclusion. Our mission is directly tied to the humanity, dignity and inherent value of each employee, patient, community member and supporter. Our commitment to learning across our differences and similarities make us stronger. We seek employees who bring different and innovative ways of seeing the world and solving problems. Fred Hutch is in pursuit of becoming an anti-racist organization. We are committed to ensuring that all candidates hired share our commitment to diversity, anti-racism and inclusion.
The Lampe lab in the Translational Research Program at the Fred Hutchinson Cancer Center has an opening for postdoctoral fellows interested in translating autoantibodies produced by B lymphocytes into tumor diagnostic and therapeutic agents. Our lab integrates state-of-the-art methods from biochemistry, cellular and molecular biology, and immunology to isolate tumor-specific autoantibodies directly from cancer patients.
A major focus of our lab is to study how B cells and the autoantibodies they produce recognize and target tumor antigens. We’ve demonstrated tumor-specific autoantibodies can be excellent biomarkers of lung tumorigenesis and can be detected prior to diagnosis (see our recent publications in AJCCRM 2019, JNM 2022 and STM 2023, PUBMED#’s 30422669, 35483965, 36630482). Using our unique approach of capturing autoantibodies bound to their native tumor derived epitopes ex vivo, we’ve shown tumor-specific autoantibodies target posttranslational modifications with high specificity. With this knowledge, we’ve isolated posttranslational tumor-specific B cells directly from patients. Our goal is to translate these findings into antibody-based theranostic applications.
Depending on a fellow’s interests, we have projects in lung cancer early detection assays, immunoPET imaging, chimeric antigen receptor T cells, and antibody drug conjugates. Most of our work is completed using highly sought cohorts of human samples, but we also utilize patient-derived xenografts, xenografts and genetically engineered mouse models. Other techniques include immunofluorescence microscopy, western blotting, immunohistochemistry, molecular engineering, flow cytometry and microarray piezoelectric printing.
Fellows will be involved all aspects of research, from experimental design to manuscript preparation and publication. A successful candidate must have excellent communication and organizational skills, the ability to develop creative approaches to experimental design, and thrive both in independent and collaborative research. Our lab is committed to maintaining a supportive and inclusive environment and are searching for highly motivated fellows who fit this ethos. In terms of career development, our autoantibody platform is widely applicable to diseases including cancer, autoimmunity, and infectious diseases. Previous lab fellows have gone into both industry and academia highlighting a strength of our translational lab.
Fred Hutchinson Cancer Center has a mandatory COVID-19 vaccine requirement, with exceptions only for approved medical or religious accommodations. As a condition of employment, newly hired employees must, prior to their first day of employment:
Provide proof of being fully vaccinated against COVID-19 ; OR
Initiate the accommodations process to request a religious or medical accommodation (medical accommodations require a healthcare provider’s certification).
A statement describing your commitment and contributions toward greater diversity, equity, inclusion, and antiracism in your career or that will be made through your work at Fred Hutch is requested of all finalists.
The annual base salary range for this position is from $65,484 to $100,000 and pay offered will be based on experience and qualifications. This position may be eligible for relocation assistance.
Fred Hutchinson Cancer Center offers employees a comprehensive benefits package designed to enhance health, well-being, and financial security. Benefits include medical/vision, dental, flexible spending accounts, life, disability, retirement, family life support, employee assistance program, onsite health clinic, tuition reimbursement, paid vacation (12-22 days per year), paid sick leave (12-25 days per year), paid holidays (13 days per year), paid parental leave (up to 4 weeks), and partially paid sabbatical leave (up to 6 months).
Software Powered by iCIMS